239 related articles for article (PubMed ID: 16767418)
1. Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial.
Teipel SJ; Drzezga A; Bartenstein P; Möller HJ; Schwaiger M; Hampel H
Psychopharmacology (Berl); 2006 Jul; 187(1):86-94. PubMed ID: 16767418
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of therapeutic response to donepezil by positron emission tomography.
Shimada A; Hashimoto H; Kawabe J; Higashiyama S; Kai T; Kataoka K; Tagawa R; Kawarada Y; Nakanishi A; Inoue K; Shiomi S; Kiriike N
Osaka City Med J; 2011 Jun; 57(1):11-9. PubMed ID: 22106763
[TBL] [Abstract][Full Text] [Related]
3. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study.
Tune L; Tiseo PJ; Ieni J; Perdomo C; Pratt RD; Votaw JR; Jewart RD; Hoffman JM
Am J Geriatr Psychiatry; 2003; 11(2):169-77. PubMed ID: 12611746
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
5. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease.
Krishnan KR; Charles HC; Doraiswamy PM; Mintzer J; Weisler R; Yu X; Perdomo C; Ieni JR; Rogers S
Am J Psychiatry; 2003 Nov; 160(11):2003-11. PubMed ID: 14594748
[TBL] [Abstract][Full Text] [Related]
6. The changes of cortical metabolism associated with the clinical response to donepezil therapy in traumatic brain injury.
Kim YW; Kim DY; Shin JC; Park CI; Lee JD
Clin Neuropharmacol; 2009; 32(2):63-8. PubMed ID: 18978490
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
8. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.
Kaasinen V; Någren K; Järvenpää T; Roivainen A; Yu M; Oikonen V; Kurki T; Rinne JO
J Clin Psychopharmacol; 2002 Dec; 22(6):615-20. PubMed ID: 12454562
[TBL] [Abstract][Full Text] [Related]
9. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study.
Mazza M; Capuano A; Bria P; Mazza S
Eur J Neurol; 2006 Sep; 13(9):981-5. PubMed ID: 16930364
[TBL] [Abstract][Full Text] [Related]
10. Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease.
Tanaka M; Namiki C; Thuy DH; Yoshida H; Kawasaki K; Hashikawa K; Fukuyama H; Kita T
J Neurol Sci; 2004 Oct; 225(1-2):135-41. PubMed ID: 15465097
[TBL] [Abstract][Full Text] [Related]
11. Does the cholinesterase inhibitor, donepezil, benefit both declarative and non-declarative processes in mild to moderate Alzheimer's disease?
Winstein CJ; Bentzen KR; Boyd L; Schneider LS
Curr Alzheimer Res; 2007 Jul; 4(3):273-6. PubMed ID: 17627484
[TBL] [Abstract][Full Text] [Related]
12. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy.
Winblad B; Wimo A; Engedal K; Soininen H; Verhey F; Waldemar G; Wetterholm AL; Haglund A; Zhang R; Schindler R
Dement Geriatr Cogn Disord; 2006; 21(5-6):353-63. PubMed ID: 16508298
[TBL] [Abstract][Full Text] [Related]
13. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.
Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E
J Neurol Sci; 2012 Nov; 322(1-2):96-101. PubMed ID: 22959283
[TBL] [Abstract][Full Text] [Related]
14. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex.
Kuhl DE; Minoshima S; Frey KA; Foster NL; Kilbourn MR; Koeppe RA
Ann Neurol; 2000 Sep; 48(3):391-5. PubMed ID: 10976649
[TBL] [Abstract][Full Text] [Related]
15. Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy.
Modrego PJ; Fayed N; Errea JM; Rios C; Pina MA; Sarasa M
Eur J Neurol; 2010 Mar; 17(3):405-12. PubMed ID: 19874395
[TBL] [Abstract][Full Text] [Related]
16. Predicting the neural effect of switching from donepezil to galantamine based on single-photon emission computed tomography findings in patients with Alzheimer's disease.
Oka M; Nakaaki S; Negi A; Miyata J; Nakagawa A; Hirono N; Mimura M
Psychogeriatrics; 2016 Mar; 16(2):121-34. PubMed ID: 26114924
[TBL] [Abstract][Full Text] [Related]
17. Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients.
Nobili F; Vitali P; Canfora M; Girtler N; De Leo C; Mariani G; Pupi A; Rodriguez G
Clin Neurophysiol; 2002 Aug; 113(8):1241-8. PubMed ID: 12140003
[TBL] [Abstract][Full Text] [Related]
18. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.
Courtney C; Farrell D; Gray R; Hills R; Lynch L; Sellwood E; Edwards S; Hardyman W; Raftery J; Crome P; Lendon C; Shaw H; Bentham P;
Lancet; 2004 Jun; 363(9427):2105-15. PubMed ID: 15220031
[TBL] [Abstract][Full Text] [Related]
19. Donepezil versus vitamin E in Alzheimer's disease: Part 2: mild versus moderate-severe Alzheimer's disease.
Onofrj M; Thomas A; Luciano AL; Iacono D; Di Rollo A; D'Andreamatteo G; Di Iorio A
Clin Neuropharmacol; 2002; 25(4):207-15. PubMed ID: 12151908
[TBL] [Abstract][Full Text] [Related]
20. Do lesions involving the cortical cholinergic pathways help or hinder efficacy of donepezil in patients with Alzheimer's disease?
Fukui T; Hieda S; Bocti C
Dement Geriatr Cogn Disord; 2006; 22(5-6):421-31. PubMed ID: 16974095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
